Johnson & Johnson 2007 Annual Report (10-K) Summary
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 30, 2007. Johnson & Johnson is a holding company with over 250 operating companies and approximately 119,200 employees worldwide. The company operates through three primary segments: Consumer (baby care, skin care, OTC pharmaceuticals), Pharmaceutical (prescription drugs), and Medical Devices and Diagnostics. The company is incorporated in New Jersey and trades on the New York Stock Exchange.
Key Financial Metrics
Note: Specific consolidated revenue, net income, and cash flow totals are incorporated by reference to the Annual Report (Exhibit 13) and are not explicitly stated in the provided text. The following specific metrics are available:
- Research and Development (R&D): $7,680 million for 2007 (up from $7,125 million in 2006 and $6,462 million in 2005).
- Stock Repurchases (Q4 2007): The company repurchased 29,539,500 shares under its public program and 15,981,300 shares outside the program. The average price paid per share ranged from $65.61 to $67.63.
- Valuation Accounts (Schedule II): Total valuation and qualifying accounts (including rebates, returns, promotions, and doubtful accounts) ended at $3,292 million for 2007.
- Equity Compensation: As of December 30, 2007, 242,288,840 securities were issuable upon exercise of outstanding options, with a weighted average exercise price of $53.63.
- Market Value: The aggregate market value of common stock held by non-affiliates was approximately $178 billion as of the end of the second fiscal quarter.
Material Changes and Operational Highlights
- Patent Expirations and Competition: Sales of DURAGESIC declined 10.1% to $1.2 billion due to generic competition following patent expiration. Combined sales of DURAGESIC and EPREX accounted for approximately 4% of worldwide sales in 2007.
- Key Product Patents: The basic patent for RISPERDAL expired in the U.S. in December 2007, though a pediatric extension grants exclusivity through June 2008. The patent for TOPAMAX is scheduled to expire in September 2008, with a potential pediatric extension pending.
- Revenue Concentration: RISPERDAL and REMICADE accounted for approximately 6% and 5% of total revenues, respectively, in 2007.
- Capital Allocation: In July 2007, the Board authorized a $10 billion stock repurchase program. As of December 30, 2007, approximately $94.9 million worth of shares remained available for purchase under the plan (based on closing price).
Outlook, Risks, and Management Commentary
- Regulatory Environment: The company faces increasing scrutiny regarding drug pricing, reimbursement levels (Medicare/Deficit Reduction Act), and business practices. Regulatory agencies have broad powers including product recalls and sanctions.
- Legal Proceedings: The company is involved in various Superfund proceedings regarding environmental remediation. Management believes these will not have a material adverse effect on financial position.
- Internal Controls: Management concluded that internal controls over financial reporting were effective as of December 30, 2007, a conclusion audited by PricewaterhouseCoopers LLP.
- Seasonality: Sales do not reflect significant seasonality, though spending on advertising and R&D is typically heavier in the fourth quarter.
Investor Verification Checklist
- Verify the impact of the RISPERDAL and TOPAMAX patent expirations on future Pharmaceutical segment revenue.
- Review the full Annual Report (Exhibit 13) for consolidated revenue, net income, and cash flow figures not detailed in this summary.
- Assess the status of the $10 billion stock repurchase program and its impact on liquidity and share count.
- Monitor regulatory developments regarding drug pricing and reimbursement policies in the U.S. and international markets.
- Examine the Legal Proceedings section (Note 18 in the Annual Report) for details on environmental liabilities and other litigation.